Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 2
Submit an article Journal homepage
37
Views
28
CrossRef citations to date
0
Altmetric
Brief Report

Efficacy and Tolerability of Alemtuzumab (CAMPATH-1H) in the Salvage Treatment of B-Cell Chronic Lymphocytic Leukemia—Change of Regimen Needed?

K RIEGER Medizinische Klinik III, Universitätsklinikum Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, GermanyCorrespondence[email protected]
,
U VON GRÜNHAGEN Onkologische Schwerpunktpraxis Cottbus, Germany
,
T FIETZ Medizinische Klinik III, Universitätsklinikum Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany
,
E THIEL Onkologische Schwerpunktpraxis Cottbus, Germany
&
W KNAUF Medizinische Klinik III, Universitätsklinikum Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany
Pages 345-349 | Received 16 Jun 2003, Published online: 03 Aug 2009

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Raimundo Fernando Bezares, German Stemelin, Alicia Diaz, Daniel Argentieri, Emilio Lanari Zubiaur, Guy Garay, Miguel Bartomioli, Ricardo Ryser & Gustavo Milone. (2011) Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leukemia & Lymphoma 52:10, pages 1936-1941.
Read now

Articles from other publishers (27)

Rod Balhorn & Monique Cosman Balhorn. (2020) Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers. Oncotarget 11:35, pages 3315-3349.
Crossref
Marianna M. Henry & Terry L. Noah. 2019. Kendig's Disorders of the Respiratory Tract in Children. Kendig's Disorders of the Respiratory Tract in Children 876 885.e6 .
M. Fiegl, R. Stauder, M. Steurer, M. Mian, G. Hopfinger, Y. Brychtova, C. Skrabs, A. Zabernigg, F. Schmid, F. Haslbaur, G. Winder, A. Walder, A. Lang, D. Voskova, R. Greil, J. Mayer & G. Gastl. (2013) Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Annals of Hematology 93:2, pages 267-277.
Crossref
Jeremy L. Warner & Jon E. Arnason. (2012) Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Therapeutic Advances in Hematology 3:6, pages 375-389.
Crossref
. 2012. Facharzt Hämatologie Onkologie. Facharzt Hämatologie Onkologie e1 e61 .
Marianna M. Henry & Terry L. Noah. 2012. Kendig & Chernickâs Disorders of the Respiratory Tract in Children. Kendig & Chernickâs Disorders of the Respiratory Tract in Children 1026 1035 .
Michael Fiegl, Florian Falkner, Michael Steurer, Niklas Zojer, Georg Hopfinger, Ferdinand Haslbauer, Guntram Winder, Daniela Voskova, Johannes Andel, Alois Lang, Yvona Brychtova, Jiri Mayer, Richard Greil & Günther Gastl. (2011) Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Annals of Hematology 90:9, pages 1083-1091.
Crossref
Xavier C. Badoux, Michael J. Keating, Xuemei Wang, Susan M. O'Brien, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Susan Lerner, Hagop Kantarjian & William G. Wierda. (2011) Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 118:8, pages 2085-2093.
Crossref
S. Agrawal, W. Hope, J. Sinko & C. Kibbler. (2010) Optimizing management of invasive mould diseases. Journal of Antimicrobial Chemotherapy 66:Supplement 1, pages i45-i53.
Crossref
Genovefa Papanicolaou & Jayesh Mehta. 2011. Principles and Practice of Cancer Infectious Diseases. Principles and Practice of Cancer Infectious Diseases 27 38 .
M. Fiegl, M. Erdel, I. Tinhofer, Y. Brychtova, A. Panovska, M. Doubek, K. Eigenberger, C. Fonatsch, G. Hopfinger, H. Mühlberger, A. Zabernigg, F. Falkner, G. Gastl, J. Mayer & R. Greil. (2010) Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Annals of Oncology 21:12, pages 2410-2419.
Crossref
Maajid Mumtaz Peerzada, Timothy P. Spiro & Hamed A. Daw. (2010) Pulmonary toxicities of biologics: a review. Anti-Cancer Drugs 21:2, pages 131-139.
Crossref
Michael Fiegl & Jiri Mayer. 2010. Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy, and Prognosis 343 358 .
M. Fiegl, G. Gastl, G. Hopfinger, K. Eigenberger, A. Zabernigg, T. Schenk, F. Falkner, A. Falkner, S. Sodia, M. Doubek, Y. Brychtova, A. Panovska, R. Greil & J. Mayer. (2008) Alemtuzumab in chronic lymphocytic leukaemia, other lymphoproliferative disease and autoimmune disorders. memo - Magazine of European Medical Oncology 1:4, pages 211-222.
Crossref
P Ljungman, R de la Camara, C Cordonnier, H Einsele, D Engelhard, P Reusser, J Styczynski & K Ward. (2008) Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplantation 42:4, pages 227-240.
Crossref
Benjamin Creelan & Andrés Ferber. (2008) A Fatal Case of Alemtuzumab-Associated Interstitial Pneumonitis. American Journal of Therapeutics 15:1, pages 82-84.
Crossref
Winnie W. Cheung, Eric Tse, Anskar Y.H. Leung, Kwok-Yung Yuen & Yok-Lam Kwong. (2007) Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. American Journal of Hematology 82:2, pages 108-111.
Crossref
Thierry Vial, Jacques Descotes, Felix Braun & Matthias Behrend. 2007. 383 423 .
Jan Eucker, Orhan Sezer & Wolfgang Knauf. 2007. Facharzt Hämatologie Onkologie. Facharzt Hämatologie Onkologie 415 462 .
Thomas Fietz & Eckhard Thiel. 2007. Targeted Therapies in Cancer. Targeted Therapies in Cancer 153 163 .
I. Dimopoulou, A. Bamias, P. Lyberopoulos & M.A. Dimopoulos. (2006) Pulmonary toxicity from novel antineoplastic agents. Annals of Oncology 17:3, pages 372-379.
Crossref
Karin A. Thursky, Leon J. Worth, John F. Seymour, H. Miles Prince & Monica A. Slavin. (2005) Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. British Journal of Haematology 132:1, pages 3-12.
Crossref
Jean-David Bouaziz, Nicolas Ortonne, Jérôme Giustiniani, Valérie Schiavon, Delphine Huet, Martine Bagot & Armand Bensussan. (2005) Circulating Natural Killer Lymphocytes Are Potential Cytotoxic Effectors Against Autologous Malignant Cells in Sezary Syndrome Patients. Journal of Investigative Dermatology 125:6, pages 1273-1278.
Crossref
Deborah Davison & Anna D. Schaal. (2005) Alemtuzumab (Campath® 1-H). Clinical Journal of Oncology Nursing 9:5, pages 630-632.
Crossref
Simon D. J. Gibbs, David A. Westerman, Christopher McCormack, John F. Seymour & H. Miles Prince. (2005) Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T‐cell lymphoproliferative disorders. British Journal of Haematology 130:1, pages 87-91.
Crossref
Simon D. J. Gibbs, Kirsten E. Herbert, Christopher McCormack, John F. Seymour & H. Miles Prince. (2004) Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome. European Journal of Haematology 73:6, pages 447-449.
Crossref
. (2004) Current Awareness in Hematological Oncology. Hematological Oncology 22:2, pages 73-84.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.